Company research
BioNTech SE
CIK 1776985Updated Sep 24, 2026
SecurityBNTX · NASDAQ · adr
BNTX price & chart
Loading TradingView…
NASDAQ:BNTX on TradingView ↗In the news
Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -1,136,100,000Source | -665,300,000Source | 930,300,000Source | 9,434,400,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | — | — | — | — |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | -9,800,000Source | 0Source | 5,500,000Source | -31,500,000Source |
| AdjustmentsForFinanceCostsEUR | 21,400,000Source | 27,400,000Source | 7,900,000Source | 18,900,000Source |
| AdjustmentsForFinanceIncomeEUR | 423,900,000Source | 648,500,000Source | 519,600,000Source | 265,300,000Source |
| AdjustmentsForSharebasedPaymentsEUR | 106,200,000Source | 100,900,000Source | 51,400,000Source | 108,600,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsEUR | -6,600,000Source | -109,500,000Source | -298,000,000Source | 625,500,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesEUR | — | 0Source | 0Source | 484,300,000Source |
| GeneralAndAdministrativeExpenseEUR | 514,400,000Source | 531,100,000Source | 495,000,000Source | 484,700,000Source |
| GoodwillEUR | 367,900,000Source | 380,600,000Source | 362,500,000Source | 61,200,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | -3,800,000Source | 389,200,000Source | 482,900,000Source | 4,222,100,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | 11,000,000Source | 13,500,000Source | 5,400,000Source | 21,500,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | 337,000,000Source | 474,900,000Source | 258,200,000Source | 29,300,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 39,600,000Source | 43,600,000Source | 40,300,000Source | 41,100,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 6,700,000Source | 0Source | 300,000Source | 800,000Source |
| ProceedsFromIssuingSharesEUR | — | 0Source | 0Source | 110,500,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | — | — | — | 600,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 18,000,000Source | 2,300,000Source | 100,000Source | 18,800,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | 0.28Source | 0.27Source | 0.27Source |
| AverageEffectiveTaxRatenumber | -0.08Source | 0.02Source | 0.22Source | 0.27Source |
| BasicEarningsLossPerShareEUR/shares | -4.7Source | -2.77Source | 3.87Source | 38.78Source |
| CurrentTaxExpenseIncomeEUR | 11,400,000Source | -2,300,000Source | 243,100,000Source | 3,629,600,000Source |
| DeferredTaxExpenseIncomeEUR | 73,900,000Source | -10,100,000Source | 12,700,000Source | -109,900,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | -73,900,000Source | 80,000,000Source | -12,700,000Source | 109,900,000Source |
| DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 57,200,000Source | — | — | — |
| DepreciationRightofuseAssetsEUR | 42,700,000Source | 45,600,000Source | 45,200,000Source | 58,800,000Source |
| DilutedEarningsLossPerShareEUR/shares | -4.7Source | -2.77Source | 3.83Source | 37.77Source |
| EmployeeBenefitsExpenseEUR | 1,029,700,000Source | 931,200,000Source | 698,600,000Source | 605,500,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | 106,300,000Source | 100,900,000Source | 51,400,000Source | 108,000,000Source |
| FinanceCostsEUR | 69,800,000Source | 27,400,000Source | 23,900,000Source | 18,900,000Source |
| FinanceIncomeEUR | 423,900,000Source | 664,000,000Source | 519,600,000Source | 330,300,000Source |
| GeneralAndAdministrativeExpenseEUR | 514,400,000Source | 531,100,000Source | 495,000,000Source | 484,700,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 500,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsEUR | 85,300,000Source | -12,400,000Source | 255,800,000Source | 3,519,700,000Source |
| InterestExpenseEUR | 14,200,000Source | — | — | — |
| InterestExpenseOnLeaseLiabilitiesEUR | 8,200,000Source | 8,600,000Source | 5,700,000Source | 5,100,000Source |
| NetForeignExchangeLossEUR | 48,400,000Source | 0Source | 16,000,000Source | 0Source |
| OtherEmployeeExpenseEUR | 57,000,000Source | — | — | — |
| Other ExpensesEUR | — | — | 7,900,000Source | — |
| OtherFinanceCostEUR | 7,200,000Source | 12,600,000Source | — | — |
| OtherIncomeEUR | 103,100,000Source | — | — | — |
| OtherOperatingIncomeExpenseEUR | -903,700,000Source | -670,900,000Source | — | — |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | 4,700,000Source | 3,500,000Source | 4,100,000Source | 2,100,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | -1,136,100,000Source | -665,300,000Source | 930,300,000Source | 9,434,400,000Source |
| ProfitLossBeforeTaxEUR | -1,050,800,000Source | -677,700,000Source | 1,186,100,000Source | 12,954,100,000Source |
| ProfitLossFromOperatingActivitiesEUR | -1,404,900,000Source | -1,314,300,000Source | 690,400,000Source | 12,642,700,000Source |
| ResearchAndDevelopmentExpenseEUR | 2,104,900,000Source | 2,254,200,000Source | 1,783,100,000Source | 1,537,000,000Source |
| RevenueFromInterestEUR | — | — | 357,600,000Source | 48,500,000Source |